Coverage
-
November 08, 2022
Three weeks after Teva Pharmaceuticals opened a patent infringement suit by accusing Eli Lilly and Co. of free riding on intellectual property undergirding its migraine drug, Lilly told the jury Tuesday its rival is the real culprit after it "hopped into a de-risked market."
2 other articles on this case.
View all »